This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More
by Zacks Equity Research
The biotech sector remains in focus with pipeline updates on coronavirus treatments.
Why Dynavax Technologies (DVAX) Stock Might be a Great Pick
by Zacks Equity Research
Dynavax Technologies (DVAX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Dynavax Technologies (DVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead Increases Enrollment Target, Pharma Rally Continues
by Ritujay Ghosh
Substantial progress has been made over the past few weeks with pharmaceutical companies speeding up development of coronavirus vaccines.
Dynavax Technologies (DVAX) in Focus: Stock Moves 9.1% Higher
by Zacks Equity Research
Dynavax Technologies (DVAX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Gilead Brings Likely Coronavirus Cure, Pharma Rallies on R&D
by Ritujay Ghosh
Shares of Gilead Science Inc. (GILD) rally on media reports that severe coronavirus patients were responding positively to the company's experimental treatment, remdesivir.
Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up
by Ritujay Ghosh
If successful, the Sanofi (SNY) and GlaxoSmithKline plc (GSK) vaccine would be available in the second half of 2021. Shares of drugmakers jumped on the news.
Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress
by Sweta Jaiswal, FRM
The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development
by Sweta Jaiswal, FRM
The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
Dynavax Technologies (DVAX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -3.03% and -11.29%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Dynavax Technologies (DVAX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Dynavax (DVAX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Dynavax (DVAX) stock based on the movements in the options market lately.
Dynavax Technologies (DVAX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -22.50% and 5.07%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Dynavax Technologies (DVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How to Find Top-Ranked Stocks Under $10 to Buy
by Benjamin Rains
Here are 5 stocks of the over 30 highly-ranked stocks trading under $10 a share that made it through this week's screen...
Dynavax Technologies Corporation (DVAX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Dynavax Technologies Corporation (DVAX).
Dynavax Technologies (DVAX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -4.76% and 4.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Dynavax Technologies Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Dynavax Technologies Corporation (DVAX) has been struggling lately, but the selling pressure may be coming to an end soon.
Dynavax (DVAX) to Cut Jobs and Focus on Vaccine Business
by Zacks Equity Research
Dynavax (DVAX) announces restructuring measures to focus on vaccine business. The CEO of the company will retire on Aug 1, 2019.
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 7.46% and -3.94%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Dynavax Technologies (DVAX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dynavax Technologies (DVAX) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dynavax (DVAX) Catches Eye: Stock Jumps 9.8%
by Zacks Equity Research
Dynavax (DVAX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Dynavax Technologies (DVAX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -6.78% and -24.23%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
5 of the Best-Performing Biotech Stocks of 2017
by Arpita Dutt
With 2017 coming to an end, it is time to take a look at the performance of the biotech sector and some of the best-performing biotech stocks including XOMA (XOMA).